Visit Lonza at CPHI Booth 6F2: advance your molecule to market faster

Published: 4-Sep-2026 Featured companies: Lonza
Manufacturing Drug Delivery Research & Development

Meet Lonza experts at CPHI Booth 6F2 for coffee and insights, and discover integrated solutions and strategies to bring complex therapies to market faster and smarter

Visit Lonza at CPHI Booth 6F2: advance your molecule to market faster
Visit Lonza at Booth 6F2 at CPHI to discover how we help transform complex molecules into life-changing therapies through integrated development and manufacturing solutions. Meet our experts across small molecules, biologics, bioconjugates and specialised modalities. Enjoy a drink from our barista-served coffee station while discussing your projects with our experts.

Join our presentations:

  • 6 October, 1:45 PM | Accelerating the Medicines of Tomorrow to IND: Building Next-Generation Biologics with Future Clinical Success in Mind | Next-Gen Bio, 12F49 | Tracey Appleton
  • 6 October, 2:15 PM | The Future of Commercial Spray Drying: Supporting the Medicines of Tomorrow | 10K69 | Jason Bertola and Francois Ricard
  • 7 October, 2:45 PM | Building the Future of Bioconjugate Supply: Integrating Payload-Linkers, Manufacturing and Commercial Scale-Up | 2A132 | Régis Lelou

Stop by Booth 6F2 to connect with our experts, gain valuable insights, and discover how Lonza can help bring your innovations to patients faster.

CPHI - Meeting Request

Featured companies

As a dedicated CDMO serving the healthcare industry, we bring life-enhancing and life-saving treatments to market for our customers and their patients. We are a pioneer and...
See more

You may also like

Manufacturing
Lonza launches rapid custom media prototyping service to accelerate early bioprocess development

Lonza launches rapid custom media prototyping service to accelerate early bioprocess development

Read more
Rapid access to custom liquid and powder media helps scientists move from formulation design to process decisions faster, while supporting a clearer path to future GMP manufacturing

Trending Articles

  1. Novartis and BMS slam breaks on gene therapy trials after adverse events Three patients have reportedly died in Novartis' experimental trials of its CAR-T therapy for autoimmune conditions, causing the pharma giant to halt eight of its clinical trials, with BMS pausing enrollment for its own CAR-T treatment for similar issues
  2. Syntegon launches pilot-scale tablet coater for flexible OSD manufacturing The new Sepion 75 tablet coater is designed to support flexible batch processing, containment of highly potent APIs and direct scale-up from pilot to commercial production
  3. Tezspire demonstrates positive Phase III results in eosinophilic esophagitis Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52
  4. Marchesini Group showcases pharma and aseptic solutions at CPHI 2026 Pharmaceutical packaging, filling and digital technologies will be on display at the Milan exhibition

Relevant companies

See more

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Manufacturing
Lonza launches rapid custom media prototyping service to accelerate early bioprocess development

Lonza launches rapid custom media prototyping service to accelerate early bioprocess development

Rapid access to custom liquid and powder media helps scientists move from formulation design to process decisions faster, while supporting a clearer path to future GMP manufacturing
Manufacturing
Lonza delivered strong H1 2026 performance across all business platforms and upgrades full-year 2026 margin outlook

Lonza delivered strong H1 2026 performance across all business platforms and upgrades full-year 2026 margin outlook

In H1 2026, Lonza delivered sales of CHF 3.4 billion with +16.0% CER sales growth
Manufacturing
Lonza and Engitix announce license agreement to advance targeted ADC Development

Lonza and Engitix announce license agreement to advance targeted ADC Development

Lonza grants Engitix target-specific license for GlycoConnect, HydraSpace and SYNtecan E linker-payload technologies for ADC development
Research & Development
Lonza acquires rights to Nona's TfR1 blood-brain barrier technology and expands strategic collaboration

Lonza acquires rights to Nona's TfR1 blood-brain barrier technology and expands strategic collaboration

Nona Biosciences’ BBB technology, combined with Lonza’s biologics development and bioconjugation capabilities, aims to enable development for central nervous system (CNS) therapies
Research & Development
Lonza expands strategic collaboration with leading US biopharmaceutical company

Lonza expands strategic collaboration with leading US biopharmaceutical company

The tailor-made comprehensive offering spans a diversified clinical and commercial portfolio of innovative modalities, including process intensification and drug product manufacturing
Research & Development
Lonza and InduPro reveal licensing agreement to advance next-generation ADC therapeutics

Lonza and InduPro reveal licensing agreement to advance next-generation ADC therapeutics

The agreement enables InduPro to leverage Lonza platforms to develop targeted oncology therapies
Drug Delivery
AmMax Bio licenses antibody-drug conjugate technology for haematological cancers from Lonza

AmMax Bio licenses antibody-drug conjugate technology for haematological cancers from Lonza

New agreement provides AmMax with access to Lonza’s GlycoConnect, HydraSpace, and SYNtecan linker-payload technologies | Agreement to target development of novel antibody-drug conjugates (ADCs) for oncology indications
Subscribe now